DEXMETHYLPHENIDATE HYDROCHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Dexmethylphenidate is a central nervous system (CNS) stimulant. Its mechanism of action in ADHD is not fully understood, but it is believed to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
| Metabolism | Dexmethylphenidate is primarily metabolized via deesterification to d-ritalinic acid, which has little to no pharmacological activity. The metabolism is mediated by carboxylesterase CES1A1. |
| Excretion | Renal (78-97% as metabolites and unchanged drug, with approximately 50% as de-esterified metabolites and 30% as unchanged drug) |
| Half-life | 2-4 hours (immediate-release); 4-5 hours (extended-release); clinical context: short half-life necessitates multiple daily dosing for immediate-release formulations |
| Protein binding | 12-19% bound to plasma proteins, primarily albumin |
| Volume of Distribution | 3.3-4.8 L/kg; clinical meaning: indicates extensive tissue distribution and penetration into tissues including the brain |
| Bioavailability | Approximately 22-25% following oral administration (immediate-release) due to first-pass metabolism; extended-release formulations have similar bioavailability |
| Onset of Action | Immediate-release: 30-60 minutes orally; Extended-release: 1-2 hours orally |
| Duration of Action | Immediate-release: 3-6 hours; Extended-release: 8-12 hours; clinical notes: duration varies with formulation; tolerance may develop with chronic use |
Initial: 5 mg orally twice daily (morning and noon) with or without food; titrate in increments of 5 mg weekly; maximum 20 mg twice daily (40 mg/day).
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). For severe impairment (CrCl <30 mL/min), reduce dose by 50%. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Avoid use or reduce dose by 75%. |
| Pediatric use | Children 6 years and older: Initial 5 mg once or twice daily (morning and noon); increase by 5 mg at weekly intervals; maximum 20 mg twice daily. Weight-based: 0.3 mg/kg/day divided twice daily, max 1 mg/kg/day. |
| Geriatric use | Start at 2.5 mg once daily in the morning; increase by 2.5 mg weekly as tolerated; maximum 20 mg twice daily. Monitor for insomnia, appetite loss, and cardiovascular effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
MAOIs are contraindicated due to risk of hypertensive crisis May exacerbate pre-existing psychosis and cause peripheral vasculopathy.
| Breastfeeding | Excretion into human milk is unknown; however, methylphenidate is present in breast milk. M/P ratio not established for dexmethylphenidate. Due to potential for serious adverse reactions in nursing infants, including insomnia, irritability, and growth suppression, breastfeeding is not recommended during therapy. |
| Teratogenic Risk | Animal studies have shown teratogenic effects at doses 40 times the human dose. Human data is limited; however, first trimester exposure may be associated with a small increased risk of congenital heart defects. Second and third trimester exposure may increase risks of preterm delivery, low birth weight, and neonatal withdrawal syndrome. Use only if potential benefit justifies risk. |
■ FDA Black Box Warning
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including dexmethylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence during therapy.
| Common Effects | narcolepsy |
| Serious Effects |
["Known hypersensitivity to dexmethylphenidate or other components of the product.","Concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI (risk of hypertensive crisis).","Glaucoma (angle-closure glaucoma due to mydriatic effect).","Tics or family history of Tourette's syndrome (may exacerbate tics).","Severe hypertension, heart failure, arrhythmias, or recent myocardial infarction (based on risk of cardiovascular events)."]
| Precautions | ["Serious cardiovascular events (sudden death, stroke, myocardial infarction) in patients with pre-existing structural cardiac abnormalities or other serious heart problems.","Blood pressure and heart rate increase; monitor closely in all patients, especially those with hypertension or tachycardia.","Psychiatric adverse events (e.g., exacerbation of pre-existing psychosis, manic episodes, aggressive behavior) may occur.","Long-term suppression of growth (weight and height) in children; monitor growth during treatment.","Seizures: may lower seizure threshold in patients with prior seizure history or EEG abnormalities.","Peripheral vasculopathy, including Raynaud's phenomenon: use with caution in patients with pre-existing vascular disorders.","Visual disturbances (difficulty with accommodation, blurred vision) have been reported."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight gain. Assess for signs of preterm labor and placental insufficiency. Fetal monitoring should include growth ultrasounds and nonstress testing in third trimester if continued use. Neonatal monitoring for withdrawal symptoms (including irritability, hyperphagia, and drowsiness) for 48 hours postpartum. |
| Fertility Effects | In animal studies, doses up to 20 mg/kg/day (approximately 40 times human dose) did not impair fertility in rats. Human data on fertility effects are lacking. Caution in patients planning pregnancy. |